Skip to content

Advertisement

Articles

Page 1 of 33

  1. Content type: Research article

    Ligands for the Toll-like receptor (TLR) family can induce activation of cells of the innate immune system and are widely studied for their potential to enhance adaptive immunity. Conjugation of TLR2-ligand Pa...

    Authors: Gijs G. Zom, Marian M. J. H. P. Willems, Selina Khan, Tetje C. van der Sluis, Jan Willem Kleinovink, Marcel G. M. Camps, Gijsbert A. van der Marel, Dmitri V. Filippov, Cornelis J. M. Melief and Ferry Ossendorp

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:146

    Published on:

  2. Content type: Case report

    Novel approaches with checkpoint inhibitors in immunotherapy continue to be essential in the treatment of non-small cell lung cancer (NSCLC). However, the low rate of primary response and the development of ac...

    Authors: Lucas C. Adam, Junaid Raja, Johannes M. Ludwig, Adebowale Adeniran, Scott N. Gettinger and Hyun S. Kim

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:147

    Published on:

  3. Content type: Research article

    Regulatory B (Breg) cells represent one of the B cell subsets that infiltrate solid tumors and exhibit distinct phenotypes in different tumor microenvironments. However, the phenotype, function and clinical re...

    Authors: Linsen Ye, Qi Zhang, Yusheng Cheng, Xiaolong Chen, Guoying Wang, Mengchen Shi, Tong Zhang, Yingjiao Cao, Hang Pan, Liting Zhang, Genshu Wang, Yinan Deng, Yang Yang and Guihua Chen

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:145

    Published on:

  4. Content type: Research article

    Immunotherapy has ushered in a new era of cancer therapy, and this is also applicable to therapy of hepatocellular carcinoma (HCC). In this context, effective development of therapeutic strategies requires an ...

    Authors: Yu-Tzu Liu, Tai-Chung Tseng, Ruey-Shyang Soong, Chun-Yi Peng, Yu-Hsing Cheng, Shiu-Feng Huang, Tsung-Hsien Chuang, Jia-Horng Kao and Li-Rung Huang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:144

    Published on:

  5. Content type: Research article

    Immune-mediated diarrhea and colitis (IMDC) can limit immune checkpoint inhibitors (ICIs) treatment, which is efficacious for advanced malignancies. Steroids and infliximab are commonly used to treat it. These...

    Authors: Hamzah Abu-Sbeih, Faisal S. Ali, Dana Alsaadi, Joseph Jennings, Wenyi Luo, Zimu Gong, David M. Richards, Aline Charabaty and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:142

    Published on:

  6. Content type: Research article

    Checkpoint inhibitors have not been effective for prostate cancer as single agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by the U.S. Food and ...

    Authors: Fatima Karzai, David VanderWeele, Ravi A. Madan, Helen Owens, Lisa M. Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael L. Beshiri, Kathleen Kelly, Venkatesh Krishnasamy, Sunmin Lee, Min-Jung Lee, Akira Yuno, Jane B. Trepel…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:141

    Published on:

  7. Content type: Review

    Chimeric Antigen Receptor (CAR) T cell therapies – adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with h...

    Authors: Michael M. Boyiadzis, Madhav V. Dhodapkar, Renier J. Brentjens, James N. Kochenderfer, Sattva S. Neelapu, Marcela V. Maus, David L. Porter, David G. Maloney, Stephan A. Grupp, Crystal L. Mackall, Carl H. June and Michael R. Bishop

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:137

    Published on:

  8. Content type: Research article

    The anti-tumor immunity of natural killer (NK) cells can be paralyzed by the CD73-induced generation of immunosuppressive adenosine from precursor ATP within the hypoxic microenvironment of solid tumors. In an...

    Authors: Jiao Wang, Kyle B. Lupo, Andrea M. Chambers and Sandro Matosevic

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:136

    Published on:

  9. Content type: Review

    Immunotherapy is at the forefront of modern oncologic care. Various novel therapies have targeted all three layers of tumor biology: tumor, niche, and immune system with a range of promising results. One emerg...

    Authors: Junaid Raja, Johannes M. Ludwig, Scott N. Gettinger, Kurt A. Schalper and Hyun S. Kim

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:140

    Published on:

  10. Content type: Review

    Identification of biomarkers in cancer immunotherapy that predict therapeutic response and/or limit adverse events are a critical need in the field. To address recent progress and hurdles around cancer biomark...

    Authors: Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, David R. Kaufman, Samir N. Khleif and Ena Wang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:138

    Published on:

  11. Content type: Research article

    A high density of tumor-infiltrating CD8+ T cells and CD20+ B cells correlates with prolonged survival in patients with a wide variety of human cancers, including high-grade serous ovarian carcinoma (HGSC). Howev...

    Authors: Iva Truxova, Lenka Kasikova, Michal Hensler, Petr Skapa, Jan Laco, Ladislav Pecen, Lucie Belicova, Ivan Praznovec, Michael J. Halaska, Tomas Brtnicky, Eva Salkova, Lukas Rob, Roman Kodet, Jeremy Goc, Catherine Sautes-Fridman, Wolf Herman Fridman…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:139

    Published on:

  12. Content type: Commentary

    Recent randomized phase III trials (KEYNOTE-407 and IMpower131) reported that adding anti-programmed death (ligand) 1 (anti-PD-(L)1) antibodies in combination with taxane-platinum improve the therapeutic effic...

    Authors: Yaxiong Zhang, Huaqiang Zhou and Li Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:135

    Published on:

  13. Content type: Research article

    Poly (ADP-ribose) polymerase inhibitors (PARPi) prevent single-stranded DNA repair. Olaparib is a PARPi approved for the treatment of BRCA mutant ovarian and breast carcinoma. Emerging clinical data suggest a ...

    Authors: Kathleen E. Fenerty, Michelle Padget, Benjamin Wolfson, Sofia R. Gameiro, Zhen Su, John H. Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong and James W. Hodge

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:133

    Published on:

  14. Content type: Clinical trials monitor

    AGI-101H is an allogeneic gene modified whole cell therapeutic melanoma vaccine, evaluated in over 400 melanoma patients in the adjuvant and therapeutic settings. We present updated long-term survival results ...

    Authors: Jacek Mackiewicz, Tomasz Burzykowski, Dariusz Iżycki and Andrzej Mackiewicz

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:134

    Published on:

  15. Content type: Research article

    Merkel cell carcinoma (MCC) is an aggressive skin cancer that frequently responds to anti-PD-1 therapy. MCC is associated with sun exposure and, in 80% of cases, Merkel cell polyomavirus (MCPyV). MCPyV-specifi...

    Authors: Natalie J. Miller, Candice D. Church, Steven P. Fling, Rima Kulikauskas, Nirasha Ramchurren, Michi M. Shinohara, Harriet M. Kluger, Shailender Bhatia, Lisa Lundgren, Martin A. Cheever, Suzanne L. Topalian and Paul Nghiem

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:131

    Published on:

  16. Content type: Case report

    Currently, there is no established standard of care for patients with metastatic CSCC. Based on the mechanisms of CSCC carcinogenesis has been postulated that these tumors may be amenable to PD-1/PD-L1 blockade.

    Authors: Leandro J. C. Oliveira, Aline B. L. Gongora, Felipe G. Barbosa, Carlos H. dos Anjos and Rodrigo R. Munhoz

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:130

    Published on:

  17. Content type: Research article

    Anti-programmed cell death 1 (PD-1) antibodies have demonstrated improved overall survival (OS) and progression-free survival (PFS) in a subset of patients with metastatic or locally advanced non-small cell lu...

    Authors: Aixa E. Soyano, Bhagirathbhai Dholaria, Julian A. Marin-Acevedo, Nancy Diehl, David Hodge, Yan Luo, Rami Manochakian, Saranya Chumsri, Alex Adjei, Keith L. Knutson and Yanyan Lou

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:129

    Published on:

  18. Content type: Review

    Escalating healthcare costs are necessitating the practice of value-based oncology. It is crucial to critically evaluate the economic impact of influential but expensive therapies such as immune checkpoint inh...

    Authors: Vivek Verma, Tanja Sprave, Waqar Haque, Charles B. Simone II, Joe Y. Chang, James W. Welsh and Charles R. Thomas Jr

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:128

    Published on:

  19. Content type: Research article

    Interleukin-12 (IL-12) is a promising candidate for cancer immunotherapy because of its ability to activate a number of host immune subsets that recognize and destroy cancer cells. We found that human hepatoce...

    Authors: Ian Lai, Srividya Swaminathan, Virginie Baylot, Adriane Mosley, Renumathy Dhanasekaran, Meital Gabay and Dean W. Felsher

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:125

    Published on:

  20. Content type: Case report

    Immunotherapy with immune checkpoint inhibitors has radically changed the management of a broad spectrum of tumors. In contrast, only very limited information is available about the efficacy of these therapies...

    Authors: Francesco Sabbatino, Antonio Marra, Luigi Liguori, Giosuè Scognamiglio, Celeste Fusciello, Gerardo Botti, Soldano Ferrone and Stefano Pepe

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:126

    Published on:

  21. Content type: Case report

    MMR-D pancreatic cancer have been reported to respond to checkpoint inhibitor therapy. Here, we report the first case of acquired resistance to immunotherapy in MMR-D pancreatic cancer.

    Authors: Zishuo Ian Hu, Matthew D. Hellmann, Jedd D. Wolchok, Monika Vyas, Jinru Shia, Zsofia K. Stadler, Luis A. Diaz Jr and Eileen M. O’Reilly

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:127

    Published on:

  22. Content type: Research article

    Nivolumab plus ipilimumab improves overall survival and is associated with less toxicity compared with sunitinib in the first-line setting of advanced renal-cell carcinoma (RCC). The current study aimed to ass...

    Authors: Bin Wu, Qiang Zhang and Jie Sun

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:124

    Published on:

  23. Content type: Research article

    T lymphocytes and HLA expression on tumor cell both influence prognostic of localized colorectal cancer, but their role following chemotherapy in patients with liver metastatic colorectal cancer (mCRC) was not...

    Authors: Fanny Ledys, Quentin Klopfenstein, Caroline Truntzer, Laurent Arnould, Julie Vincent, Leila Bengrine, Romain Remark, Romain Boidot, Sylvain Ladoire, Francois Ghiringhelli and Valentin Derangere

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:123

    Published on:

  24. Content type: Case report

    Immune-directed therapies have become front-line therapy for melanoma and are transforming the management of advanced disease. In refractory cases, multi-modal immunoncology (IO) approaches are being utilized,...

    Authors: David M. Miller, Ryan M. Trowbridge, Anupam Desai and Reed E. Drews

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:122

    Published on:

  25. Content type: Commentary

    Innate lymphoid cells (ILCs) are increasingly being recognized for their ability to impact both innate and adaptive immune cells in diverse contexts. ILCs have been observed in all secondary lymphoid tissues, ...

    Authors: Sarah Q. Crome and Pamela S. Ohashi

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:121

    Published on:

  26. Content type: Research article

    The Janus kinase (JAK) and signal transduction and activation of transcription (STAT) signaling pathway is an attractive target in multiple cancers. Activation of the JAK-STAT pathway is important in both tumo...

    Authors: Matthew J. Reilley, Patricia McCoon, Carl Cook, Paul Lyne, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes, John Nemunaitis, Nathan Fowler, Michael Curran, Qinying Liu, Tianyuan Zhou, Joanna Schmidt, Minji Jo, Samantha J. Lee…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:119

    Published on:

  27. Content type: Commentary

    Commentary on « Ipilimumab induced vasculitis » by Padda A. et al., J Immunother Cancer. 2018;6:12. The authors diagnosed a small vessel vasculitis following treatment with anti-CTLA-4 (ipilimumab) for a resec...

    Authors: Thibault Comont, Vincent Sibaud, Loïc Mourey, Pierre Cougoul and Odile Beyne-Rauzy

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:120

    Published on:

  28. Content type: Research article

    The pancreatic cancer vaccine, GVAX, induces novel lymphoid aggregates in the otherwise immune quiescent pancreatic ductal adenocarcinoma (PDAC). GVAX also upregulates the PD-1/PD-L1 pathway, and a pre-clinica...

    Authors: May Tun Saung, Stephen Muth, Ding Ding, Dwayne L. Thomas II, Alex B. Blair, Takahiro Tsujikawa, Lisa Coussens, Elizabeth M. Jaffee and Lei Zheng

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:118

    Published on:

  29. Content type: Short report

    Acute myeloid leukemia (AML) is the most common acute leukemia amongst adults with a 5-year overall survival lower than 30%. Emerging evidence suggest that immune alterations favor leukemogenesis and/or AML re...

    Authors: Regina Jitschin, Domenica Saul, Martina Braun, Sehmus Tohumeken, Simon Völkl, Roman Kischel, Michael Lutteropp, Cedric Dos Santos, Andreas Mackensen and Dimitrios Mougiakakos

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:116

    Published on:

  30. Content type: Research article

    Neoadjuvant immunotherapy utilizing novel combinations has the potential to transform the standard of care for locally/regionally advanced melanoma. We hypothesized that neoadjuvant ipilimumab in combination w...

    Authors: Ahmad Tarhini, Yan Lin, Huang Lin, Zahra Rahman, Priyanka Vallabhaneni, Prateek Mendiratta, James F. Pingpank, Matthew P. Holtzman, Erik C. Yusko, Julie A. Rytlewski, Uma N. M. Rao, Robert L. Ferris and John M. Kirkwood

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:112

    Published on:

  31. Content type: Research article

    We assessed the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with previously treated metastatic adrenocortical carcinoma (mACC).

    Authors: Christophe Le Tourneau, Christopher Hoimes, Corrine Zarwan, Deborah J. Wong, Sebastian Bauer, Rainer Claus, Martin Wermke, Subramanian Hariharan, Anja von Heydebreck, Vijay Kasturi, Vikram Chand and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:111

    Published on:

  32. Content type: Research article

    Combination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor types including advanced or metastatic renal cell carc...

    Authors: Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang and Hans J Hammers

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:109

    Published on:

  33. Content type: Position article and guidelines

    To develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of immuno-oncology (IO) treatments.

    Authors: Apostolia M. Tsimberidou, Laura A. Levit, Richard L. Schilsky, Steven D. Averbuch, Daniel Chen, John M. Kirkwood, Lisa M. McShane, Elad Sharon, Kathryn F. Mileham and Michael A. Postow

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:108

    Published on:

  34. Content type: Research article

    Nivolumab is approved for the treatment of refractory metastatic renal cell carcinoma. Patterns and predictors of progressive disease (PD) on nivolumab, and outcomes in such patients are lacking.

    Authors: Haris Zahoor, Pedro C. Barata, Xuefei Jia, Allison Martin, Kimberly D. Allman, Laura S. Wood, Timothy D. Gilligan, Petros Grivas, Moshe C. Ornstein, Jorge A. Garcia and Brian I. Rini

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:107

    Published on:

  35. Content type: Research article

    Several studies have established a correlation between the VEGF–VEGFR2 axis and an immunosuppressive microenvironment; this immunosuppression can be overcome by anti-angiogenic reagents, such as ramucirumab (R...

    Authors: Yasuko Tada, Yosuke Togashi, Daisuke Kotani, Takeshi Kuwata, Eichi Sato, Akihito Kawazoe, Toshihiko Doi, Hisashi Wada, Hiroyoshi Nishikawa and Kohei Shitara

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:106

    Published on:

  36. Content type: Case report

    The use of immune checkpoint inhibitors is increasing in cancer therapy today. It is critical that treatment teams become familiar with the organ systems potentially impacted by immune-related adverse events a...

    Authors: Kendall F. Moseley, Jarushka Naidoo, Clifton O. Bingham, Michael A. Carducci, Patrick M. Forde, Geoffrey T. Gibney, Evan J. Lipson, Ami A. Shah, William H. Sharfman and Laura C. Cappelli

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:104

    Published on:

  37. Content type: Research article

    Immune-related enterocolitis (irEC) is the most common serious complication from checkpoint inhibitors (CPIs). The current front-line treatment for irEC, high-dose corticosteroids (CS), have significant side e...

    Authors: Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, Junsheng Ma, Roland L Bassett Jr, Noha Abdel-Wahab, Jaime Anderson, Jennifer E Davis, Jocelyn Joseph, Marc Uemura, Ali Noman, Hamzah Abu-Sbeih, Cassian Yee, Rodabe Amaria, Sapna Patel, Hussein Tawbi…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:103

    Published on:

  38. Content type: Research article

    Immunoscore, as a prognostic tool defined to quantify in situ immune cell infiltrates, appears to be superior to the TNM staging system. In esophageal squamous cell carcinoma (ESCC), no immunoscore has been es...

    Authors: Jingjing Duan, Yongwei Xie, Lijuan Qu, Lingxiong Wang, Shunkai Zhou, Yu Wang, Zhongyi Fan, Shengsheng Yang and Shunchang Jiao

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:100

    Published on:

  39. Content type: Research article

    Nivolumab, an immune checkpoint inhibitor, has revolutionized the treatment of many cancers. Due to its novel mechanisms of action, nivolumab induces a distinct profile of adverse events. Currently, the incide...

    Authors: Bin Zhao, Hong Zhao and Jiaxin Zhao

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:101

    Published on:

  40. Content type: Review

    The treatment of metastatic melanoma patients with autologous tumor-infiltrating lymphocytes (TIL) shows robust, reproducible, clinical responses in clinical trials executed in several specialized centers over...

    Authors: Maartje W. Rohaan, Joost H. van den Berg, Pia Kvistborg and John B. A. G. Haanen

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:102

    Published on:

  41. Content type: Research article

    Women diagnosed with breast cancer within 5 years postpartum (PPBC) have poorer prognosis than age matched nulliparous women, even after controlling for clinical variables known to impact disease outcomes. Thr...

    Authors: Nathan D. Pennock, Holly A. Martinson, Qiuchen Guo, Courtney B. Betts, Sonali Jindal, Takahiro Tsujikawa, Lisa M. Coussens, Virginia F. Borges and Pepper Schedin

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:98

    Published on:

  42. Content type: Case report

    Malignant angiomyolipoma is an uncommon tumor of the class of perivasciular epithelioid cell neoplasms (PEComas). These tumors are characteristically driven by deleterious mutations in the tumor suppressors TSC1 ...

    Authors: Michael Lattanzi, Fang-Ming Deng, Luis A. Chiriboga, Alisa N. Femia, Shane A. Meehan, Gopa Iyer, Martin H. Voss, Yuliya Sundatova, William C. Huang and Arjun V. Balar

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:97

    Published on:

2017 Journal Metrics

Advertisement